The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 (GLP-1) receptor signalling. Here, we translate these findings into patients by conducting a randomized, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, James L, Lyons, Hannah S, Walker, Jessica K, Yiangou, Andreas, Grech, Olivia, Alimajstorovic, Zerin, Greig, Nigel H, Li, Yazhou, Tsermoulas, Georgios, Brock, Kristian, Mollan, Susan P, Sinclair, Alexandra J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151178/
https://www.ncbi.nlm.nih.gov/pubmed/36907221
http://dx.doi.org/10.1093/brain/awad003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151178/
https://www.ncbi.nlm.nih.gov/pubmed/36907221
http://dx.doi.org/10.1093/brain/awad003

Ejemplares similares